In this webinar, Dr. Tom Polasek, a clinical pharmacologist at Certara Strategic Consulting, explained how he used the Simcyp Simulator to predict olanzapine exposure in individual patients. By watching this webinar you will learn how PBPK modeling and simulation technology can be re-purposed to support model-informed precision dosing.
PRINCETON, NJ – Feb. 27, 2018 – Certara today announced that it has published two papers demonstrating proof of concept for its Virtual Twin™ technology.
PRINCETON, NJ – July 25, 2017 – Certara today announced that Professor Piet van der Graaf, PharmD, PhD, vice president and head of Certara QSP, is co-chairing the NIH workshop entitled “QSP and Drug Discovery: Filling the Gaps in Current Models of the R&D Process for Neurotherapeutics.”
The current version of the database includes clinical safety and efficacy information on treatment options currently approved or in development for chronic lower back pain. The current version of the database includes information on all systemic pharmacological interventions. This includes mono and combination therapy with NSAIDs, acetaminophen, opioids, COX-2 inhibitors, norepinephrine reuptake inhibitors, anti-NGF, anti-epileptic drugs (AEDs), antidepressants, and muscle relaxants.
